AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Nano Research Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article

Develop potential multi-target drugs by self-assembly of quercetin with amino acids and metal ion to achieve significant efficacy in anti-Alzheimer’s disease

Chunling Zhu( ), Yuheng Yang, Xiaowen Li, Xingyu Chen, Xucong Lin, Xiaoping Wu
Institute of Food Safety and Environment Monitoring, College of Chemistry, Fuzhou University, Fuzhou 350116, China
Show Author Information

Graphical Abstract

Self-assembled nanoparticles (NPs) were developed as multi-target drugs (MTDs) by using9-fluorenylmethyloxycarbonyl-tryptophan (Fmoc-Trp), quercetin, and Fe2+ as buildingblocks through coordination and electrostatic interaction to generate Fmoc-Trp-Fe2+-Quercetin (FTFQ) NPs. The prepared self-assembled NPs exhibited enhanced therapeuticeffects to Alzheimer’s disease (AD) zebrafish through simultaneously acting on severaltargets such as inhibiting β-site APP cleaving enzyme (BACE1) activity, reducing Aβaggregation, inducing Aβ fibrils disaggregation, and eliminating toxic reactive oxygenspecies (ROS).

Abstract

Exploring multi-target drugs (MTDs) is a prevalent method against Alzheimer’s disease (AD). However, the current developed MTDs based on the “framework combination” technique or using flavonoids have not realized better healing effects owing to a complex metabolic process and low bioavailability. Here, we propose an alternative strategy to develop self-assembled nanoparticles (NPs) as MTDs using 9-fluorenylmethyloxycarbonyl-tryptophan (Fmoc-Trp), quercetin (Que), and Fe2+ as building blocks through coordination and electrostatic interaction to generate Fmoc-Trp-Fe2+-Que (FTFQ) NPs. Whether in cell or in vivo, FTFQ NPs exhibited considerable biocompatibility attributing to the inherent biological affinity of assembly units. By combining the advantages of assemble approach and nanostructures, the obtained FTFQ NPs greatly enhanced the bioavailability of Que and displayed synergistic therapeutic effects through reducing Aβ aggregation in direct/indirect means and eliminating the toxicity induced by ROS and Aβ oligomer/fibrils. Furthermore, FTFQ NPs could obviously restore the AD zebrafish’s mobility and stimulus response ability. More importantly, developing self-assembly NPs as MTDs could be an efficient and general method to promote other novel MTDs by extending the assemble units to other drugs, peptides, and metal ions. Based on above benefits, these self-assembled NPs could be as potential MTDs and show great promising application in AD treatment.

Keywords

Alzheimer’s diseasemulti-target drugs (MTDs)self-assembled nanoparticles (NPs)quercetin (Que)

Electronic Supplementary Material

Download File(s)
12274_2021_4066_MOESM1_ESM.pdf (1.6 MB)

References

1

Scheltens, P.; De Strooper, B.; Kivipelto, M.; Holstege, H.; Chételat, G.; Teunissen, C. E.; Cummings, J.; van der Flier, W. M. Alzheimer's disease. Lancet 2021, 397, 1577–1590.
Crossref Google Scholar
2

Ballard, C.; Aarsland, D.; Cummings, J.; O’Brien, J.; Mills, R.; Molinuevo, J. L.; Fladby, T.; Williams, G.; Doherty, P.; Corbett, A. et al. Drug repositioning and repurposing for Alzheimer disease. Nat. Rev. Neurol. 2020, 16, 661–673.
Crossref Google Scholar
3

Golde, T. E.; DeKosky, S. T.; Galasko, D. Alzheimer's disease: The right drug, the right time. Science 2018, 362, 1250–1251.
Crossref Google Scholar
4

Chen, J. L.; Zhang, P. Y.; Abe, M.; Aikawa, H.; Zhang, L. Y.; Frank, A. J.; Zembryski, T.; Hubbs, C.; Park, H.; Withka, J. et al. Design, optimization, and study of small molecules that target tau pre-mRNA and affect splicing. J. Am. Chem. Soc. 2020, 142, 8706–8727.
Crossref Google Scholar
5

Ma, M. M.; Liu, Z. Q.; Gao, N.; Pi, Z. F.; Du, X. B.; Ren, J. S.; Qu, X. G. Self-protecting biomimetic nanozyme for selective and synergistic clearance of peripheral amyloid-β in an Alzheimer’s disease model. J. Am. Chem. Soc. 2020, 142, 21702–21711.
Crossref Google Scholar
6

Zhang, F.; Zhong, R. J.; Cheng, C.; Li, S.; Le, W. D. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease. Acta Pharmacol. Sin. 2021, 42, 1382–1389.
Crossref Google Scholar
7

van der Kant, R.; Goldstein, L. S. B.; Ossenkoppele, R. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nat. Rev. Neurosci. 2020, 21, 21–35.
Crossref Google Scholar
8

Irwin, M. R.; Vitiello, M. V. Implications of sleep disturbance and inflammation for Alzheimer's disease dementia. Lancet Neurol. 2019, 18, 296–306.
Crossref Google Scholar
9

Bachurin, S. O.; Bovina, E. V.; Ustyugov, A. A. Drugs in clinical trials for Alzheimer's disease: The major trends. Med. Res. Rev. 2017, 37, 1186–1225.
Crossref Google Scholar
10

Cao, J. Q.; Hou, J. W.; Ping, J.; Cai, D. M. Advances in developing novel therapeutic strategies for Alzheimer’s disease. Mol. Neurodegener. 2018, 13, 64.
Crossref Google Scholar
11

Kim, M.; Kang, J.; Lee, M.; Han, J.; Nam, G.; Tak, E.; Kim, M. S.; Lee, H. J.; Nam, E.; Park, J. et al. Minimalistic principles for designing small molecules with multiple reactivities against pathological factors in dementia. J. Am. Chem. Soc. 2020, 142, 8183–8193.
Crossref Google Scholar
12

Geldenhuys, W. J.; Youdim, M. B. H.; Carroll, R. T.; Van der Schyf, C. J. The emergence of designed multiple ligands for neurodegenerative disorders. Prog. Neurobiol. 2011, 94, 347–359.
Crossref Google Scholar
13

Schneider, L. S.; Geffen, Y.; Rabinowitz, J.; Thomas, R. G.; Schmidt, R.; Ropele, S.; Weinstock, M.; Group, L. S. Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. Neurology 2019, 93, e1474–e1484.
Crossref Google Scholar
14

Perez, D. I.; Martinez, A.; Gil, C.; Campillo, N. E. From bitopic inhibitors to multitarget drugs for the future treatment of Alzheimer’s disease. Curr. Med. Chem. 2015, 22, 3789–3806.
Crossref Google Scholar
15

Blaikie, L.; Kay, G. Kong Thoo Lin, P. Current and emerging therapeutic targets of Alzheimer's disease for the design of multi-target directed ligands. MedChemComm 2019, 10, 2052–2072.
Crossref Google Scholar
16

Bolognesi, M. L. Polypharmacology in a single drug: Multitarget drugs. Curr. Med. Chem. 2013, 20, 1639–1645.
Crossref Google Scholar
17

Benek, O.; Korabecny, J.; Soukup, O. A perspective on multi-target drugs for Alzheimer's disease. Trends Pharmacol. Sci. 2020, 41, 434–445.
Crossref Google Scholar
18

Khan, H.; Ullah, H.; Aschner, M.; Cheang, W. S.; Akkol, E. K. Neuroprotective effects of quercetin in Alzheimer's disease. Biomolecules 2020, 10, 59.
Crossref Google Scholar
19

Russo, M.; Spagnuolo, C.; Tedesco, I.; Bilotto, S.; Russo, G. L. The flavonoid quercetin in disease prevention and therapy: Facts and fancies. Biochem. Pharmacol. 2012, 83, 6–15.
Crossref Google Scholar
20

Zaplatic, E.; Bule, M.; Shah, S. Z. A.; Uddin, S.; Niaz, K. Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer's disease. Life Sci. 2019, 224, 109–119.
Crossref Google Scholar
21

Suganthy, N.; Devi, K. P.; Nabavi, S. F.; Braidy, N.; Nabavi, S. M. Bioactive effects of quercetin in the central nervous system: Focusing on the mechanisms of actions. Biomed. Pharmacother. 2016, 84, 892–908.
Crossref Google Scholar
22

Jiménez-Aliaga, K.; Bermejo-Bescós, P.; Benedí, J.; Martín-Aragón, S. Quercetin and rutin exhibit antiamyloidogenic and fibril-disaggregating effects in vitro and potent antioxidant activity in APPswe cells. Life Sci. 2011, 89, 939–945.
Crossref Google Scholar
23

Shi, Y.; Liang, X. C.; Zhang, H.; Wu, Q. L.; Qu, L.; Sun, Q. Quercetin protects rat dorsal root ganglion neurons against high glucose-induced injury in vitro through Nrf-2/HO-1 activation and NF-κB inhibition. Acta Pharmacol. Sin. 2013, 34, 1140–1148.
Crossref Google Scholar
24

Ansari, M. A.; Abdul, H. M.; Joshi, G.; Opii, W. O.; Butterfield, D. A. Protective effect of quercetin in primary neurons against Aβ(1-42): Relevance to Alzheimer's disease. J. Nutr. Biochem. 2009, 20, 269–275.
Crossref Google Scholar
25

Amanzadeh, E.; Esmaeili, A.; Abadi, R. E. N.; Kazemipour, N.; Pahlevanneshan, Z.; Beheshti, S. Quercetin conjugated with superparamagnetic iron oxide nanoparticles improves learning and memory better than free quercetin via interacting with proteins involved in LTP. Sci. Rep. 2019, 9, 6876.
Crossref Google Scholar
26

Paula, P. C.; Angelica Maria, S. G.; Luis, C. H.; Gloria Patricia, C. G. Preventive effect of quercetin in a triple transgenic Alzheimer’s disease mice model. Molecules 2019, 24, 2287.
Crossref Google Scholar
27

Rifaai, R. A.; Mokhemer, S. A.; Saber, E. A.; El-Aleem, S. A. A.; El-Tahawy, N. D. G. Neuroprotective effect of quercetin nanoparticles: A possible prophylactic and therapeutic role in Alzheimer’s disease. J. Chem. Neuroanat. 2020, 107, 101795.
Crossref Google Scholar
28

Kumar, P.; Sharma, G.; Kumar, R.; Singh, B.; Malik, R.; Katare, O. P.; Raza, K. Promises of a biocompatible nanocarrier in improved brain delivery of quercetin: Biochemical, pharmacokinetic and biodistribution evidences. Int. J. Pharm. 2016, 515, 307–314.
Crossref Google Scholar
29

Sun, D. D.; Li, N.; Zhang, W. W.; Zhao, Z. W.; Mou, Z. P.; Huang, D. H.; Liu, J.; Wang, W. Y. Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s disease. Colloids Surf. B:Biointerf. 2016, 148, 116–129.
Crossref Google Scholar
30

Liu, H. H.; Han, Y. B.; Wang, T. T.; Zhang, H.; Xu, Q.; Yuan, J. X.; Li, Z. Targeting microglia for therapy of Parkinson’s disease by using biomimetic ultrasmall nanoparticles. J. Am. Chem. Soc. 2020, 142, 21730–21742.
Crossref Google Scholar
31

Li, Y. X.; Zou, Q. L.; Yuan, C. Q.; Li, S. K.; Xing, R. R.; Yan, X. H. Amino acid coordination driven self-assembly for enhancing both the biological stability and tumor accumulation of curcumin. Angew. Chem., Int. Ed. 2018, 57, 17084–17088.
Crossref Google Scholar
32

Li, S. K.; Zou, Q. L.; Xing, R. R.; Govindaraju, T.; Fakhrullin, R.; Yan, X. H. Peptide-modulated self-assembly as a versatile strategy for tumor supramolecular nanotheranostics. Theranostics 2019, 9, 3249–3261.
Crossref Google Scholar
33

Mukherjee, S.; Madamsetty, V. S.; Bhattacharya, D.; Chowdhury, S. R.; Paul, M. K.; Mukherjee, A. Recent advancements of nanomedicine in neurodegenerative disorders theranostics. Adv. Funct. Mater. 2020, 30, 2003054.
Crossref Google Scholar
34

Liu, Z. X.; Li, X. L.; Wu, X. P.; Zhu, C. L. A dual-inhibitor system for the effective antifibrillation of Aβ40 peptides by biodegradable EGCG-Fe(III)/PVP nanoparticles. J. Mater. Chem. B 2019, 7, 1292–1299.
Crossref Google Scholar
35

Vácha, R.; Linse, S.; Lund, M. Surface effects on aggregation kinetics of amyloidogenic peptides. J. Am. Chem. Soc. 2014, 136, 11776–11782.
Crossref Google Scholar
36

Gaumet, M.; Vargas, A.; Gurny, R.; Delie, F. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm. 2008, 69, 1–9.
Crossref Google Scholar
37

Erdogan, G.; Karadag, R.; Dolen, E. Potentiometrie and spectrophotometric determination of the stability constants of quercetin complexes with aluminium(III) and iron(II). Rev. Anal. Chem. 2005, 24, 247–261.
Crossref Google Scholar
38

de Castilho, T. S.; Matias, T. B.; Nicolini, K. P.; Nicolini, J. Study of interaction between metal ions and quercetin. Food Sci. Hum. Well. 2018, 7, 215–219.
Crossref Google Scholar
39

Muñoz, V. A.; Ferrari, G. V.; Sancho, M. I.; Montaña, M. P. Spectroscopic and thermodynamic study of chrysin and quercetin complexes with Cu(II). J. Chem. Eng. Data 2016, 61, 987–995.
Crossref Google Scholar
40

da Silva, W. M. B.; de Oliveira Pinheiro, S.; Alves, D. R.; de Menezes, J. E. S. A.; Magalhães, F. E. A.; Silva, F. C. O.; Silva, J.; Marinho, E. S.; de Morais, S. M. Synthesis of quercetin-metal complexes, in vitro and in silico anticholinesterase and antioxidant evaluation, and in vivo toxicological and anxiolitic activities. Neurotoxic. Res. 2020, 37, 893–903.
Crossref Google Scholar
41

Porfírio, D. A.; de Queiroz Ferreira, R.; Malagutti, A. R.; Valle, E. M. A. Electrochemical study of the increased antioxidant capacity of flavonoids through complexation with iron(II) ions. Electrochim. Acta 2014, 141, 33–38.
Crossref Google Scholar
42

Salgado, P.; Melin, V.; Contreras, D.; Moreno, Y.; Mansilla, H. D. Fenton reaction driven by iron ligands. J. Chil. Chem. Soc. 2013, 58, 2096–2101.
Crossref Google Scholar
43

Leopoldini, M.; Russo, N.; Chiodo, S.; Toscano, M. Iron chelation by the powerful antioxidant flavonoid quercetin. J. Agric. Food Chem. 2006, 54, 6343–6351.
Crossref Google Scholar
44

Murakami, K.; Irie, K. Three structural features of functional food components and herbal medicine with amyloid β42 anti-Aggregation properties. Molecules 2019, 24, 2125.
Crossref Google Scholar
45

Chow, V. W.; Mattson, M. P.; Wong, P. C.; Gleichmann, M. An overview of APP processing enzymes and products. NeuroMol. Med. 2010, 12, 1–12.
Crossref Google Scholar
46

Keskin, A. D.; Kekuš, M.; Adelsberger, H.; Neumann, U.; Shimshek, D. R.; Song, B.; Zott, B.; Peng, T. Y.; Förstl, H.; Staufenbiel, M. et al. BACE inhibition-dependent repair of Alzheimer’s pathophysiology. Proc. Natl. Acad. Sci. USA 2017, 114, 8631–8636.
Crossref Google Scholar
47

Zhu, K. C.; Peters, F.; Filser, S.; Herms, J. Consequences of pharmacological BACE inhibition on synaptic structure and function. Biol. Psychiatry 2018, 84, 478–487.
Crossref Google Scholar
48

Saleem, S.; Kannan, R. R. Zebrafish: An emerging real-time model system to study Alzheimer's disease and neurospecific drug discovery. Cell Death Discov. 2018, 4, 45.
Crossref Google Scholar
49
Jia H. R. Zhu Y. X. Duan Q. Y. Chen Z. Wu F. G. Nanomaterials meet zebrafish: Toxicity evaluation and drug delivery applications J. Control. Release 2019 311–312 301 318 10.1016/j.jconrel.2019.08.022

Jia, H. R.; Zhu, Y. X.; Duan, Q. Y.; Chen, Z.; Wu, F. G. Nanomaterials meet zebrafish: Toxicity evaluation and drug delivery applications. J. Control. Release 2019, 311–312, 301–318.
Crossref Google Scholar
50

Faridi, A.; Sun, Y. X.; Okazaki, Y.; Peng, G. T.; Gao, J.; Kakinen, A.; Faridi, P.; Zhao, M.; Javed, I.; Purcell, A. W. et al. Mitigating human IAPP amyloidogenesis in vivo with chiral silica nanoribbons. Small 2018, 14, 1802825.
Crossref Google Scholar
51

Wang, X. B.; Zhang, J. B.; He, K. J.; Wang, F.; Liu, C. F. Advances of zebrafish in neurodegenerative disease: From models to drug discovery. Front. Pharmacol. 2021, 12, 713963.
Crossref Google Scholar
52

Huang, W. H.; Li, C. S.; Shen, Z. R.; Zhu, X. Y.; Xia, B.; Li, C. Q. Development of a zebrafish model for rapid drug screening against Alzheimer's disease. J. Pharm. Pharmacol. 2016, 4, 162–173.
Crossref Google Scholar
53

Guggiana-Nilo, D. A.; Engert, F. Properties of the visible light phototaxis and UV avoidance behaviors in the larval zebrafish. Front. Behav. Neurosci. 2016, 10, 160.
Crossref Google Scholar
54

Javed, I.; Peng, G. T.; Xing, Y. T.; Yu, T. Y.; Zhao, M.; Kakinen, A.; Faridi, A.; Parish, C. L.; Ding, F.; Davis, T. P. et al. Inhibition of amyloid beta toxicity in zebrafish with a chaperone-gold nanoparticle dual strategy. Nat. Commun. 2019, 10, 3780.
Crossref Google Scholar
55

Sang, Z. P.; Wang, K. R.; Shi, J.; Liu, W. M.; Cheng, X. F.; Zhu, G. F.; Wang, Y. L.; Zhao, Y. Y.; Qiao, Z. P.; Wu, A. G. et al. The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2020, 192, 112180.
Crossref Google Scholar
Nano Research
Volume 15 Issue 6,
June 2022
Pages 5173-5182
DOI: 10.1007/s12274-021-4066-8
Cite this article:
Zhu C, Yang Y, Li X, et al. Develop potential multi-target drugs by self-assembly of quercetin with amino acids and metal ion to achieve significant efficacy in anti-Alzheimer’s disease. Nano Research, 2022, 15(6): 5173-5182. https://doi.org/10.1007/s12274-021-4066-8
Topics:
Nano biology

892

Views

10

Crossref

11

Web of Science

10

Scopus

1

CSCD

Altmetrics
Received: 10 August 2021
Revised: 07 December 2021
Accepted: 10 December 2021
Published: 14 March 2022
© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2021
Return